Develops cyclodextrin-based therapies for the treatment of neurodegenerative diseases.
Cyclo Therapeutics, Inc., headquartered in Gainesville, Florida, is a clinical-stage biotechnology company specializing in the development of cyclodextrin-based products for treating various diseases. The company's flagship drug candidate, Trappsol Cyclo, is an orphan drug currently in Phase III clinical trials for Niemann-Pick Type C disease, a rare and fatal genetic disorder affecting neurologic and other organ systems. Cyclo Therapeutics is also advancing Trappsol Cyclo for potential use in Alzheimer's disease treatment.
Beyond its therapeutic pipeline, Cyclo Therapeutics supplies cyclodextrins and related products to pharmaceutical, nutritional, and other industries. These products are primarily used in diagnostics and specialty drugs, underscoring the company's dual focus on drug development and commercialization of specialty chemicals.
Founded in 1990 as CTD Holdings, Inc., the company rebtanded to Cyclo Therapeutics, Inc. in September 2019 to better align its corporate identity with its core mission and expanding portfolio. With a strong commitment to innovation and therapeutic advancements, Cyclo Therapeutics continues to pursue novel treatments for challenging diseases through its cyclodextrin technology platform.